Paul G. Richardson

TL;DR: Particular emphasis is placed on the interface between MM cells and normal cell compartments of the BM, especially bone marrow stromal cells (BMSCs), and on the development of a series of new classes of therapeutic agents, including the proteasome inhibitor bortezomib, thalidomides and lenalidomide, which counteract specific aspects of those MM–BM interactions.

TL;DR: This was the first clinical study to evaluate the safety, tolerability, maximal‐tolerated dose (MTD), dose‐limiting toxicity (DLT), pharmacokinetics, and preliminary clinical activity of TAK‐228, an oral TORC1/2 inhibitor, in patients with MM, NHL, or WM.

TL;DR: A synthetic lethal approach enhancing oxidative stress while targeting replicative stress response, inducing tumor cell apoptosis in this patient subset of multiple myeloma patients with poor prognosis is defined.

TL;DR: It is estimated that approximately 5000 individuals of the 20 000 who were transplanted in the United States during 1998 would have been predicted to have symptoms and signs which met the criteria for VOD, and of these between 800 and 1600 persons were likely to have developed fatal illness.

TL;DR: A double-labeling protocol combining intracellular cytokeratin with epithelial cell adhesion molecule (Ep-CAM) or disialo-ganglioside (GD2) antigen (small cell lung carcinoma, neuroblastoma, melanoma antigen) was developed and examples of doubly labeled cultured cells and cancer cells from breast and small cell lung cancer patients are shown.